Synapse - Mark Kris

Results (223)

Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches

Journal Article

Drilon, A.; Wang, L.; Arcila, M. E.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; Kris, M. G.; more...
Clinical Cancer Research (2015)

Fulltext@MSK | Save

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

Journal Article

Hutchinson, K. E.; Johnson, D. B.; Johnson, A. S.; Sánchez, V.; Kuba, M.; Lu, P.; Chen, X.; Kelley, M. C.; Wang, Q.; Zhao, Z.; more...
Oncotarget (2015)

Fulltext@MSK | Save

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Journal Article

Naidoo, J.; Sima, C. S.; Rodriguez, K.; Busby, N.; Nafa, K.; Ladanyi, M.; Riely, G. J.; Kris, M. G.; Arcila, M. E.; Yu, H. A.
Cancer (2015)

Fulltext@MSK | Save

Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS)

Meeting Abstract

Pietanza, M. C.; Won, H. H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Krug, L. M.; Varghese, A. M.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers

Meeting Abstract

Drilon, A. E.; Sima, C. S.; Somwar, R.; Smith, R.; Ginsberg, M. S.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; Kris, M. G.; Rizvi, N. A.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay

Meeting Abstract

Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Journal Article

Sholl, L. M.; Aisner, D. L.; Varella-Garcia, M.; Berry, L. D.; Dias-Santagata, D.; Wistuba, I. I.; Chen, H.; Fujimoto, J.; Kugler, K.; Franklin, W. A.; more...
Journal of Thoracic Oncology (2015)

Fulltext@MSK | Save

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

Journal Article

Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S.; Gainor, J.; Shaw, A.; Hames, M.; Iams, W.; Aston, J.; Lovly, C. M.; more...
Journal of Thoracic Oncology (2015)

Fulltext@MSK | Save

MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking

Journal Article

Arcila, M. E.; Drilon, A.; Sylvester, B. E.; Lovly, C. M.; Borsu, L.; Reva, B.; Kris, M. G.; Solit, D. B.; Ladanyi, M.
Clinical Cancer Research (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable driver alterations in lung adenocarcinomas using a clinical, hybrid capture-based, next-generation sequencing assay

Meeting Abstract

Arcila, M.; Zehir, A.; Cheng, D.; Yu, H.; Kris, M.; Drilon, A.; Riely, G.; Berger, M.; Ladanyi, M.
Modern Pathology (2015)

Fulltext@MSK | Save